Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation

Vascular Pharmacology

Volumn 53, Issue 3-4, 2010, Pages 115-121

  Vassilakopoulou, M ^a   Mountzios, G ^a   Papamechael, C ^a   Protogerou, A D ^a   Aznaouridis, K ^a   Katsichti, P ^a   Venetsanou, K ^a   Dimopoulos, M A ^a   Ikonomidis, I ^a   Papadimitriou, C A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Endothelium; IL 6; Paclitaxel chemotherapy; TNF ; Vascular toxicity

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; EPIRUBICIN; INTERLEUKIN 6; NITRATE; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ENDOTHELIUM CELL; FEMALE; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VASCULAR DISEASE; VASODILATATION;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BRACHIAL ARTERY; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CISPLATIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RADIATION-SENSITIZING AGENTS; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 77956190278     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.05.002     Document Type: Article

References (52)

1. Adamson I.Y.R., Orr F.W., Young L., et al. Effects of injury and repair of the pulmonary endothelium on lung metastasis after bleomycin. J. Pathol. 1986, 150:279-287.
2. Baudin B. Toxicité endothéliale des chimiothérapies anticancereuses. Sang, Thrombose et Vaisseaux 1995, 7:175-183.
3. Bhagat K., Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997, 96:3042-3047.
4. Calver A., Collier J., Moncada S., Vallance P. Effect of local intra-arterial NG-monomethyl-l-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J. Hypertens. 1992, 10:1025-1031.
5. Calver A., Collier J., Vallance P., et al. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest. 1992, 90:2548-2554.
6. Carter T.K., Hallam T.J., Cusack N.J., Pearson J.D. Regulation of P2y-purinoceptor-mediated prostacyclin release from human endothelial cells by cytoplasmic calcium concentration. Br. J. Pharmacol. 1988, 95:1181-1190.
7. Chowienczyk P.J., Watts G.F., Cockcroft J.R., Ritter J.M. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992, 340:1430-1432.
8. Dasanu C.A. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin. Drug Saf. 2008, 7(6):703-716.
9. DeVita J.V., Lawrence T.S., Rosenberg S.A. Cancer Principles and Practice of Oncology 2008, Lippincott Williams & Wilkins, Philadelphia, USA.
10. Donehower R.C., Rowinsky E.K., Grochow L.B., et al. Phase I trial of Taxol in patients with advanced malignancies. Cancer Treat. Rep. 1987, 71:1171-1177.
11. Drachman D.E., Edelman E.R., Seifert P., et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 2000, 36:2325-2332.
12. Frangos J.A., Eskin S.G., McIntyre L.W., Ives C.L. Flow effects on prostacyclin production by cultured human endothelial cells. Science 1985, 227:1477-1479.
13. Fitzpatrick F.A., Wheeler R. The immunopharmacology of Paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int. Immunopharmacol. 2003, 3:1699-1714.
14. Hartmann J.T., Kollmannsberger C., Kanz L., Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer 1999, 83(6):866-869.
15. Heldman A.W., Cheng L., Jenkins G.M., et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4weeks in a porcine model of coronary restenosis. Circulation 2001, 103:2289-2295.
16. Ikonomidis I., Papadimitriou C., Vamvakou G., et al. Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function. Growth Factors 2008, 26(3):117-124.
17. Jaffe E.A., Grulich J., Weksler B.B., Hampel G., Watanabe K. Correlation between thrombin-induced prostacyclin production and inositol trisphosphate and cytosolic free calcium levels in cultured human endothelial cells. J. Biol. Chem. 1987, 262:8557-8565.
18. Karzan A. Tumor necrosis factor and endothelial cell death. Trends Cardiovasc. Med. 1998, 8:19-24.
19. Kasprzak J.D., Kłosińska M., Drozdz J. Clinical aspects of assessment of endothelial function. Pharmacol. Rep. 2006, 58 Suppl:33-40.
20. Kaushal V., Kaushal G.P., Mehta P., et al. Differential toxicity of anthracyclines on cultured endothelial cells. Endothelium 2004, 11(5-6):253-258.
21. Kebers F., Le Walle J.-M., Desreux J. Induction of endothelial cell apoptosis by solid tumor cells. Exp. Cell Res. 1998, 240:197-205.
22. Kerbel J.S., Viloria-Petit A., Klement G., Rak J. «Accidental» anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer 2000, 36:1248-1257.
23. Koller A., Sun D., Kaley G., et al. Role of shear stress and endothelial prostaglandins in flow and viscosity-induced dilation of arterioles in vitro. Circ. Res. 1993, 72:1276-1284.
24. Koller A., Sun D., Huang A., Kaley G. Corelease of nitric oxide and prostaglandins mediates flow-dependent dilation flow of rat gracilis muscle arterioles. Am. J. Physiol. Heart Circ. Physiol. 1994, 266:H326-H332.
25. Lazo J.S. Endothelial injury caused by antineoplastic agents. Biochem. Pharmacol. 1986, 35:1919-1923.
26. Liistro F., Stankovic G., Di Mario C., et al. First clinical experience with a Paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002, 105:1883-1886.
27. Lock R.B., Stribinskienne L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 1996, 56:4006-4012.
28. López-Miranda V., Herradón E., González C., Martín M.I. Vascular toxicity of chemotherapeutic agents. Curr. Vasc. Pharmacol. 2010, Jan 1. [Electronic publication ahead of print].
29. Luscer T.F. The endothelium and cardiovascular disease-a complex relation. N. Engl. J. Med. 1994, 330:1081-1083.
30. Mailloux A., Grenet K., Bruneel A., Beneteau-Burnat B., Vaubourdolle M., Baudin B. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur. J. Cell Biol. 2001, 80:442-449.
31. McGuire W.P., Rowinsky E.K., Rosenshein N.B., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Inter. Med. 1989, 111:273-279.
32. Miao J.-Y., Kaji K., Hayashi, Araki S. Suppression of apoptosis by inhibition of phosphatidylcholine-specific phospholipase C in vascular endothelial cells. Endothelium 1997, 5:231-239.
33. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007 Dec 27, 357(26):2666-2676.
34. Morita T., Kurihara H., Maemura K., Yoshizumi M., Yazaki Y. Disruption of cytoskeletal structures mediates shear stress-induced endothelial-1 gene expression in cultured porcine aortic endothelial cells. J. Clin. Invest. 1993, 92:1706-1712.
35. Muta M., Yanagawa T., Sai Y., Saji S., Suzuki E., Aruga T., Kuroi K., Matsumoto G., Toi M., Nakashima E. Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells. Oncology 2009, 77(3-4):182-191.
36. New P., Barohn R., Gales T., et al. Taxol neuropathy after long-term administration. Proc. Am. Assoc. Cancer Res. 1991, 32:205.
37. Oike M., Schwartz G., Sehrer J., et al. Cytoskeletal modulation of the response to mechanical stimulation in human vascular endothelial cells. Pflugers Arch. 1994, 428:569-579.
38. Peterson E.R., Crain S.M. Nerve growth factor attenuates neurotoxic effects of Taxol on spinal cord-ganglion explants from fetal mice. Science 1982, 217:377-379.
39. Petit P.X., Susin S.A., Zamzami N., Mignotte B., Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett. 1996, 396:7-13.
40. Rasenick M.M., Wang N., Yan K., et al. Specific associations between tubulin and G-proteins: participation of cytoskeletal elements in cellular signal transduction. Adv. Second Messenger Phosphoprotein Res. 1990, 24:381-386.
41. Rowinsky E.K., McGuire W.P., Guarniery T., et al. Cardiac disturbances during the administration of Taxol. J. Clin. Oncol. 1991, 9:1704-1712.
42. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667.
43. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:1561-1565.
44. Skladanowski A., Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol. 1993, 46:375-382.
45. Smith A.C., Boyd M.R. Effects of bis-chloronitrosourea (BCNU) on pulmonary and serum angiotensin-converting enzyme activity in rats. Biochem. Pharmacol. 1983, 32:3719-3722.
46. Straubinger R.M., Arnold R.D., Zhou R., Mazurchuk R., Slack J.E. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res. 2004, 24(2A):397-404.
47. Szabo C., Cuzzocrea S., Zingarelli B., O'Connor M., Salzman A.-l. Endothelial dysfunction in a rat model of endotoxic shock. J. Clin. Invest. 1997, 100:723-735.
48. Tsutsui H., Tagawa H., Kent R.L., McCollam P.L., Ishihara K., Nagatsu M., Cooper G. Role of microtubules in contractile dysfunction of hypertrophied cardiocytes. Circulation 1994, 90:533-555.
49. Wang J.H., Redmond H.P., Watson R.W.G., Condron C., Boucher-Hayes D. Introduction of heat shock protein 72 prevents neutrophil-mediated human endothelial cell necrosis. Arch. Surg. 1995, 130:1260-1265.
50. Weiss R., Donehower R.C., Wiernik P.H., et al. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 1990, 8:1263-1268.
51. Wiernik P.H., Schwartz E.L., Strauman J.J., et al. Phase I clinical and pharmacokinetic study of Taxol. Cancer Res. 1987, 47:2486-2493.
52. Zhu B.Q., Parmley W.W. Hemodynamic and vascular effects of active and passive smoking. Am. Heart J. 1995, 130:1270-1275.